Danielle Marie Brander | Scholars@Duke

Danielle Marie Brander
Assistant Professor of Medicine

Current Appointments & Affiliations

Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2021
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2016

Contact Information

2400 Pratt St Suite 5000, Durham, NC 27710
DUMC Box 3961, Durham, NC 27710
danielle.brander@duke.edu (919) 668-1000

Background
Education, Training, & Certifications
- Resident, Internal Medicine, Duke University School of Medicine 2007 - 2010
- M.D., Duke University School of Medicine 2007
Previous Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2017 - 2020
- Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2013 - 2017
Research
Selected Grants
External Relationships
- AbbVie Pharmaceuticals
- ArQule
- Ascentage
- AstraZeneca
- BeiGene
- DTRM Biopharma
- Genentech, Inc (Roche Holding)
- Juno/celgene/BMS
- MEI biopharma
- Novartis
- Pfizer Inc.
- Pharmacyclics (AbbVie)
- TG Therapeutics
- Tolero
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Kleinstern, Geffen, J Brice Weinberg, Sameer A. Parikh, Esteban Braggio, Sara J. Achenbach, Dennis P. Robinson, Aaron D. Norman, et al. “Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.” Leukemia 36, no. 1 (January 2022): 119–25. https://doi.org/10.1038/s41375-021-01344-9.
    Full Text Link to Item
  - Davids, Matthew S., Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, et al. “Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.” Blood Adv 5, no. 23 (December 14, 2021): 5332–43. https://doi.org/10.1182/bloodadvances.2021005132.
    Full Text Link to Item
  - MacDonald, Grace, Andrea Sitlinger, Michael A. Deal, Erik D. Hanson, Stephanie Ferraro, Carl F. Pieper, J Brice Weinberg, Danielle M. Brander, and David B. Bartlett. “A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia.” Sci Rep 11, no. 1 (November 30, 2021): 23137. https://doi.org/10.1038/s41598-021-02352-6.
    Full Text Link to Item
  - Stephens, Deborah M., Ken Boucher, Elizabeth Kander, Sameer A. Parikh, Erin M. Parry, Mazyar Shadman, John M. Pagel, et al. “Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.” Haematologica 106, no. 11 (November 1, 2021): 2845–52. https://doi.org/10.3324/haematol.2020.256388.
    Full Text Link to Item
  - Ruppert, Amy S., Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutre, Jennifer R. Brown, et al. “Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.” Leukemia 35, no. 10 (October 2021): 2854–61. https://doi.org/10.1038/s41375-021-01342-x.
    Full Text
  - Gordon, Max J., Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, et al. “The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 17 (September 2021): 4814–24. https://doi.org/10.1158/1078-0432.ccr-20-3993.
    Full Text
  - Ma, Shuo, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, et al. “Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.” Blood 138, no. 10 (September 2021): 836–46. https://doi.org/10.1182/blood.2020009578.
    Full Text
  - Sitlinger, Andrea, Michael A. Deal, Erwin Garcia, Dana K. Thompson, Tiffany Stewart, Grace A. MacDonald, Nicolas Devos, et al. “Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL).” Cells 10, no. 5 (May 11, 2021). https://doi.org/10.3390/cells10051165.
    Full Text Link to Item
  - Mato, Anthony R., Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, et al. “Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.” Blood 137, no. 20 (May 2021): 2817–26. https://doi.org/10.1182/blood.2020007376.
    Full Text
  - Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, et al. “Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.” Lancet Haematol 8, no. 4 (April 2021): e254–66. https://doi.org/10.1016/S2352-3026(20)30433-6.
    Full Text Link to Item
  - Slager, Susan L., Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp, Fatima Abbasi, Neil E. Kay, et al. “Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.” Blood 137, no. 15 (April 2021): 2046–56. https://doi.org/10.1182/blood.2020006322.
    Full Text
  - Eyre, Toby A., Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani, Brian T. Hill, Paul M. Barr, Erick Lansigan, et al. “Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.” Haematologica 106, no. 1 (January 1, 2021): 284–87. https://doi.org/10.3324/haematol.2019.241539.
    Full Text Link to Item
  - Hanlon, Ashley, and Danielle M. Brander. “Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.” Hematology Am Soc Hematol Educ Program 2020, no. 1 (December 4, 2020): 346–56. https://doi.org/10.1182/hematology.2020000119.
    Full Text Link to Item
  - Cuneo, Antonio, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, et al. “Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.” Cancer Med 9, no. 22 (November 2020): 8468–79. https://doi.org/10.1002/cam4.3470.
    Full Text Link to Item
  - Mato, Anthony R., Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori Leslie, John M. Pagel, Krish Patel, et al. “Outcomes of COVID-19 in patients with CLL: a multicenter international experience.” Blood 136, no. 10 (September 3, 2020): 1134–43. https://doi.org/10.1182/blood.2020006965.
    Full Text Link to Item
  - Roeker, Lindsey E., Peter Dreger, Jennifer R. Brown, Oscar B. Lahoud, Toby A. Eyre, Danielle M. Brander, Alan Skarbnik, et al. “Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.” Blood Adv 4, no. 16 (August 25, 2020): 3977–89. https://doi.org/10.1182/bloodadvances.2020001956.
    Full Text Link to Item
  - Mato, Anthony R., Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle Brander, Mazyar Shadman, et al. “Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.” Clin Cancer Res 26, no. 14 (July 15, 2020): 3589–96. https://doi.org/10.1158/1078-0432.CCR-19-3815.
    Full Text Link to Item
  - Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.
    Full Text Link to Item
  - Sitlinger, Andrea, Danielle M. Brander, and David B. Bartlett. “Impact of exercise on the immune system and outcomes in hematologic malignancies.” Blood Adv 4, no. 8 (April 28, 2020): 1801–11. https://doi.org/10.1182/bloodadvances.2019001317.
    Full Text Link to Item
  - Eichenberger, Emily M., Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, and Julia A. Messina. “A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.” Med Mycol Case Rep 27 (March 2020): 17–21. https://doi.org/10.1016/j.mmcr.2019.12.007.
    Full Text Link to Item
  - Eyre, Toby A., Lindsey E. Roeker, Christopher P. Fox, Satyen H. Gohill, Renata Walewska, Harriet S. Walter, Francesco Forconi, et al. “The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.” Br J Haematol 188, no. 6 (March 2020): 918–23. https://doi.org/10.1111/bjh.16271.
    Full Text Link to Item
  - Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.” Br J Haematol 186, no. 4 (August 2019): 637. https://doi.org/10.1111/bjh.15934.
    Full Text Link to Item
  - Davids, Matthew S., Danielle M. Brander, Haesook T. Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M. Hellman, et al. “Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.” Lancet Haematol 6, no. 8 (August 2019): e419–28. https://doi.org/10.1016/S2352-3026(19)30104-8.
    Full Text Link to Item
  - Roeker, Lindsey E., Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, et al. “Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25, no. 14 (July 2019): 4264–70. https://doi.org/10.1158/1078-0432.ccr-19-0361.
    Full Text
  - Mato, Anthony R., Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, et al. “A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.” Blood Adv 3, no. 10 (May 28, 2019): 1568–73. https://doi.org/10.1182/bloodadvances.2019000180.
    Full Text Link to Item
  - Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.” Br J Haematol 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.
    Full Text Link to Item
  - Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.” J Natl Compr Canc Netw 17, no. 1 (January 2019): 12–20. https://doi.org/10.6004/jnccn.2019.0002.
    Full Text Link to Item
  - Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.” N Engl J Med 379, no. 26 (December 27, 2018): 2517–28. https://doi.org/10.1056/NEJMoa1812836.
    Full Text Link to Item
  - Mato, Anthony R., Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Bruce D. Cheson, et al. “Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.” Am J Hematol 93, no. 11 (November 2018): 1394–1401. https://doi.org/10.1002/ajh.25261.
    Full Text Link to Item
  - Mato, Anthony R., Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, et al. “Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.” Haematologica 103, no. 9 (September 2018): 1511–17. https://doi.org/10.3324/haematol.2018.193615.
    Full Text Link to Item
  - Mato, Anthony R., Jennifer C. Samp, Geneviève Gauthier, Emi Terasawa, and Danielle M. Brander. “Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.” Cancer Biol Ther 19, no. 7 (July 3, 2018): 636–43. https://doi.org/10.1080/15384047.2018.1449616.
    Full Text Link to Item
  - Mato, Anthony R., Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, et al. “Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.” Haematologica 103, no. 5 (May 2018): 874–79. https://doi.org/10.3324/haematol.2017.182907.
    Full Text Link to Item
  - Burris, Howard A., Ian W. Flinn, Manish R. Patel, Timothy S. Fenske, Changchun Deng, Danielle M. Brander, Martin Gutierrez, et al. “Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.” Lancet Oncol 19, no. 4 (April 2018): 486–96. https://doi.org/10.1016/S1470-2045(18)30082-2.
    Full Text Link to Item
  - Thompson, Meghan, Danielle Brander, Chadi Nabhan, and Anthony Mato. “Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.” Jama Oncol 4, no. 3 (March 1, 2018): 394–400. https://doi.org/10.1001/jamaoncol.2017.2009.
    Full Text Link to Item
  - Wierda, William G., John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 11 (November 2017): 1414–27. https://doi.org/10.6004/jnccn.2017.0165.
    Full Text Link to Item
  - Mato, A. R., B. T. Hill, N. Lamanna, P. M. Barr, C. S. Ujjani, D. M. Brander, C. Howlett, et al. “Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.” Ann Oncol 28, no. 5 (May 1, 2017): 1050–56. https://doi.org/10.1093/annonc/mdx031.
    Full Text Link to Item
  - Brander, Danielle M. “Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?” Br J Haematol 176, no. 3 (February 2017): 337–40. https://doi.org/10.1111/bjh.14446.
    Full Text Link to Item
  - Seymour, John F., Shuo Ma, Danielle M. Brander, Michael Y. Choi, Jacqueline Barrientos, Matthew S. Davids, Mary Ann Anderson, et al. “Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.” Lancet Oncol 18, no. 2 (February 2017): 230–40. https://doi.org/10.1016/S1470-2045(17)30012-8.
    Full Text Link to Item
  - Strati, Paolo, Mark Lanasa, Timothy G. Call, Jose F. Leis, Danielle M. Brander, Betsy R. LaPlant, Adam M. Pettinger, et al. “Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.” Lancet Haematol 3, no. 9 (September 2016): e407–14. https://doi.org/10.1016/S2352-3026(16)30064-3.
    Full Text Link to Item
  - Friedman, Daphne R., Mark C. Lanasa, Patricia H. Davis, Sallie D. Allgood, Karen M. Matta, Danielle M. Brander, Youwei Chen, et al. “Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.” Leuk Lymphoma 55, no. 5 (May 2014): 1067–75. https://doi.org/10.3109/10428194.2013.824080.
    Full Text Link to Item
  - Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.” Leuk Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.
    Full Text Link to Item
  - Brander, Danielle M., and Anne W. Beaven. “Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.” Patient Prefer Adherence 6 (2012): 239–51. https://doi.org/10.2147/PPA.S23241.
    Full Text Link to Item
  - Bean, Gregory R., Andrew D. Bryson, Patrick G. Pilie, Vanessa Goldenberg, Joseph C. Baker, Catherine Ibarra, Danielle M. U. Brander, et al. “Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.” Clin Cancer Res 13, no. 22 Pt 1 (November 15, 2007): 6834–41. https://doi.org/10.1158/1078-0432.CCR-07-0407.
    Full Text Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles